本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 上海君实生物医药科技股份有限公司（以下简称"公司"）于2025年12月29日召开第四届董事会第十六次 会议，审议通过了《关于募集资金投资项目延期的议案》，同意将公司2022年度向特定对象发行A股股 票募集资金投资项目（以下简称"募投项目"）之"创新药研发项目"的项目实施期限延期至2028年12月 及"上海君实生物科技总部及研发基地项目"的项目实施期限延期至2026年6月。本次募投项目延期仅涉 及项目进度的变化，未改变募投项目的投资内容、投资总额、实施主体等，不会对募投项目的实施造成 实质性影响。保荐人国泰海通证券股份有限公司（以下简称"保荐人"）对本事项出具了明确的核查意 见，本事项无需提交公司股东会审议。现将相关情况公告如下： 二、募投项目的基本情况 截至2025年6月30日，公司2022年度向特定对象发行A股股票募集资金使用情况如下： 单位：人民币万元 ■ 截至2025年6月30日，公司2022年度向特定对象发行A股股票募集资金存储情况如下： 单位：人民币万元 一、募集资 ...

Core Viewpoint - Sunshine Nuohong announced the transfer of 70% equity in Shanghai Meisuke Data Co., Ltd. to Beijing Zhongjian Peilian Medical Research Institute, aiming to enhance asset operation efficiency and reduce management costs due to the subsidiary's long-term losses [1][2]. Group 1: Equity Transfer Details - Sunshine Nuohong's subsidiary, Beijing Nuohong Demai Pharmaceutical Technology Co., Ltd., signed an equity transfer agreement, selling 70% of its stake in Meisuke Data for 2 million yuan [1]. - After the transaction, Sunshine Nuohong will no longer hold any equity in Meisuke Data, which will be excluded from the company's consolidated financial statements [1]. - The transfer involves part of the fundraising project "Clinical Trial Service Platform Construction Project," which has been completed and is now operational [1]. Group 2: Financial Implications - Meisuke Data has accumulated fundraising of 17.2887 million yuan, with 4.5 million yuan being registered capital paid by Nuohong Demai [1]. - The remaining 12.7789 million yuan of the fundraising will be returned to Sunshine Nuohong's fundraising account for future investment in the "Innovative Drug R&D Project" [2]. - The company aims to improve operational efficiency and support business expansion through this equity transfer, which is a strategic decision based on the company's current situation [2].

Core Viewpoint - Haichuang Pharmaceutical announced adjustments to certain sub-projects within its "Innovative Drug R&D Project" to enhance the efficiency of fundraising, while keeping the total investment amount unchanged [2]. Group 1 - The company will hold its second board meeting and the tenth supervisory board meeting on August 13, 2025, to review the proposal for adjustments [2]. - The adjustments to the fundraising projects require approval from the company's shareholders' meeting [2].

Group 1 - The board of directors of Beijing Sunshine Nuohuo Pharmaceutical Research Co., Ltd. convened a meeting to discuss and approve changes to the use of special fundraising accounts and the establishment of new accounts [1][2] - The company agreed to change the purpose of existing fundraising accounts from various research projects to focus on "large model platform projects for peptide molecules" and "innovative drug research projects" [1][2] - New special fundraising accounts will be established by the company's subsidiaries for specific projects, ensuring that the funds are used solely for their intended purposes [1][2] Group 2 - The board approved an adjustment to the grant price of the 2025 restricted stock incentive plan from 22.78 yuan per share to 22.62 yuan per share due to the company's annual equity distribution [2][3] - This adjustment complies with relevant regulations and does not harm the interests of the company or its shareholders [2][3] - The voting results for the incentive plan adjustment showed unanimous support from the board members present [4]